Brief: Ipsen: EC Conditional Marketing Authorization For Ojemda (Tovorafenib)
22/04/2026 06:24
April 22 (Reuters) - Ipsen SA IPN.PA: EUROPEAN COMMISSION GRANTED CONDITIONAL MARKETING AUTHORIZATION FOR OJEMDA (TOVORAFENIB) Source text: ID:nGNE8Mgg8K Further company coverage: IPN.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ipsen SA
See all newsFulcrum falls after discontinuing sickle cell drug program
Fulcrum falls after discontinuing sickle cell drug program
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
Fulcrum Therapeutics falls after scrapping sickle cell drug development
Brief: Ipsen's IQIRVO Shows Meaningful Fatigue Improvements In Moderate-To-Severe PBC Patients